Data shows CancerIQ Reach closes gap between eligibility and participation in payer-supported, standard and supplemental screenings, leads to early cancer diagnoses and promotes health system loyalty story.cd/AAYYMz
ICYMI: July's highlight was our webinar with @NebraskaMed's Cancer Survivorship & Risk & Prevention Director Rachael Schmidt, APRN: "What is Campaign-Based Risk Assessment & How Does It Drive Cancer Screening Compliance?" bit.ly/4d8g9wz#precisionprevention#lungcancer
Beyond traditional clinic settings, there lies a vast opportunity to connect with individuals who might not be aware of their cancer risk or precision prevention opportunities. Learn more about CancerIQ's campaign-based screening: bit.ly/3KlUt3e#precisionprevention
CancerIQ seeks health system participants in large-scale research effort: "Validating Applications for Long-term Utility and Enhanced ROI" (VALUE) in Cancer Risk Programs Study, to document the ROI of digital interventions for genetically informed care.
bit.ly/44dbRjP
For #LynchSyndromeAwarenessDay this is your reminder that:
đź’ Lynch syndrome is common (1:279 individuals)
đź’ Lynch syndrome is actionable (increased surveillance/prevention options lead to better outcomes)
đź’ Lynch syndrome is underdiagnosed (most people are not aware that they have it)
#ColorectalCancerAwarenessMonth
There's nothing sweeter than saving lives through #precisionprevention, #earlydetection, and treatment! Happy Valentine's Day from team CancerIQ to every provider using genetic information to empower patients and get #aheadofcancer!
Learn more: bit.ly/3woogEM
Q&A: Partnering with providers for #cancer#prevention - @CancerIQ provides personalized care plans to help providers detect cancer early and prevent progression of the disease, says Feyi Ayodele, founder and CEO of CancerIQ. mobihealthnews.com/news/qa-p…
The American Cancer Society Cancer Facts & Figures 2024 report is here. With breast, prostate, colorectal (ages 0-54), and cervical (ages 30-44) cancers on the rise, it's important to get screened. Hear more from @AmerCancerCEO.
Full report: amercancer.co/cff24
A much larger pool of patients now requires access to #genetictesting given @ASCO's expanded BRCA1/2 mutation testing recommendations for all #bscm patients <65 years old. It's imperative we equip clinical teams with the tools to support increased volumes. bit.ly/48E6dbU
New germline genetic testing guidelines: All women with breast cancer diagnosis under the age of 65 should be offered germline genetic testing. They don’t need to meet any additional criteria. Thank you @ASCO for the opportunity to draft these guidelines.
ascopubs.org/doi/full/10.120…
Happy, Healthy New Year 2024 from all of us at CancerIQ!
Together, we can stay ahead of cancer, bringing hope and health to our communities. Here's to a year of breakthroughs, health, and progress!
#aheadofcancer#precisionprevention
.@CancerX is conducting its first demonstration project to merge data assets, and collaborating with industry partners (including @CancerIQ!) to build comprehensive real-world datasets in a way that’s never been done before in oncology. Learn more: bit.ly/3tmfxlt
We're thrilled to announce @AssuranceLab SOC 2 Type 2 Compliance, demonstrating that we have undergone rigorous testing & are a trusted platform for empowering health systems to scale genetically informed cancer prevention, treatment, & survivorship care.
prweb.com/releases/canceriq-…
Patient advocate @ARosen380 at @AmericanCancer shares her story & the importance of a #precisionprevention approach for high-risk patient management:
"Having Crohn’s disease put me at greater risk for colorectal cancer & as a result, every year, I have a diagnostic colonoscopy."
When the #BreastCancerAwarenessMonth pink is packed away, many women don't think about their prevention plans again until next year. Learn how CancerIQ can help you identify, assess, & manage the high-risk patients that need more than an annual screening.
bit.ly/3SyqVVv